Janssen Search
Search results
Janssen Oncology Strengthens Disease Interception Focus with TARIS’ Unique Delivery System
Janssen Oncology Strengthens Disease Interception Focus with TARIS' Unique Delivery System Aug 14, 2020 A small pretzel-shaped device designed as a novel approach for the treatment of bladder cancer attracted Janssen Oncology to TARIS Biomedical in ...
Michael Plotnick, M.D.
MICHAEL PLOTNICK, M.D. VICE PRESIDENT GLOBAL MEDICAL AFFAIRS IMMUNOLOGY Michael Plotnick, M.D. is Vice President, Global Medical Affairs for the Immunology Global Commercial Strategy Organization of Janssen Global Services. In this role, he leads a team ...
Discovering Neuroscience Innovation
Discovery “Our goal is to drive the types of discoveries that will ultimately improve the prevention, diagnosis, and treatment of neuropsychiatric, neurological, and neurodegenerative diseases for generations to come.” Simon Lovestone Global Head of ...
Hepatitis B and the Burden it Inflicts
Hepatitis B and the Burden it Inflicts Article Type: Infectious Diseases & Vaccines At Janssen, we have an ambitious goal. We strive to bring forth medical innovations that improve the lives of people affected by hepatitis to ensure future ...
Oncology Overview Page 2
Driving Toward the Elimination of Cancer At Janssen Oncology, we have a singular focus – the elimination of cancer. We are inspired by today’s tremendous progress and emerging new ideas, and we are driven by the enormous global unmet medical need in ...
Janssen Receives Positive CHMP Opinions for Novel Bispecific Antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Jul 21, 2023 Belgium Talquetamab is the first therapy targeting GPRC5D to receive a positive CHMP Opinion Teclistamab, the first BCMA-targeting bispecific antibody to be approved in Europe, receives positive CHMP Opinion for reduced, biweekly dosing ...
Janssen Receives Positive CHMP Opinion for CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) for Treatment in Earlier Lines of Relapsed and Refractory Multiple Myeloma
Feb 23, 2024 Belgium Results from the Phase 3 CARTITUDE-4 study, which supported the CHMP recommendation, showed that cilta-cel has the potential to offer significant benefit to patients in earlier lines of treatment [1] Most patients with multiple ...
Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer
Sep 16, 2024 Spain TAR-200 plus cetrelimab effective in reducing tumor size in those with muscle-invasive disease, potentially improving surgical outcomes and lowering risk of recurrence BARCELONA, September 16, 2024 – Johnson & Johnson (NYSE:JNJ) ...
Paul Duncan
PAUL DUNCAN SENIOR DIRECTOR EXTERNAL INNOVATION IMMUNOLOGY Paul Duncan is Senior Director, External Innovation for the Immunology Global Commercial Strategy Organization of Janssen Global Services. In this role, Paul is responsible for leading the overall ...
TREMFYA® (guselkumab) Demonstrates a Differentiated Binding Mechanism from Risankizumab in In Vitro Studies
Mar 03, 2023 United States Studies suggest mechanistic benefit of guselkumab by binding to cells that drive inflammation in the colon SPRING HOUSE, PENNSYLVANIA, March 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today ...